A precise solution to treat cancer.
Over 10 million people are diagnosed with cancer each year. Cancer has been called “the wound that does not heal”. Lumina’s innovative technology targets the wound characteristics of cancer to treat solid tumors and metastases.
Target is absent in healthy tissue but prevalent in nearly all solid tumors.
Target sits outside cells in the extracellular matrix, making it easier to target.
Our lead asset shows reliable uptake across multiple tumor types.
Boston, MA, September 15, 2026 – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company advancing fibrin-targeting theranostic agents, today announced that Cara Ferreira, Ph.D., Chief Executive Officer, will participate in Discovery on Target 2026, taking
Boston, MA – September 8, 2026 — Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, announced today that it has been selected as a showcase company for the 2026–2027 National Cancer Institute Small Business Innovation
